Avagenesis Corp. Announces Operational Sales Office in Taiwan and First Customer Contracts

June 1, 2015 – Calgary, Alberta: Avagenesis Corp. ("Avagenesis" or the "Company") (TSXV: VVA) is pleased to announce the formal launch of its Taiwan Sales Office, the Company's first fully-staffed and fully operational sales office in Asia. Contracts for the first cash flow generating beta systems have been signed and systems are currently in use with customers.

The recent registration of its licensed bioprocessing and cell isolation system with the Taiwan Food and Drug Administration (collectively "FDA") has driven the development of expanded marketing activities in the Company's first target market in Asia. Personnel in the Taiwan Sales Office were hired several months ago and have now undergone extensive training in support of existing beta deployments and expanded business development activity. Sales processes, marketing materials, technical/operational manuals, sales contracts, related legal documentation and other supporting materials have all been developed and finalized over recent months. In addition, the Company has positioned several dozen systems in Taiwan, ready and available for deployment. Each system placed at a customer site has the potential to generate up to USD$60,000.00 or more of cash flow annually.

The Taiwan Sales Office is located in the capital city of Taipei, and has the capacity to service customers throughout the entire country. Taiwan has a population of over 23 million people.

About Avagenesis Corp.

Avagenesis is a biotechnology company engaged in the commercialization of medical technologies for use in the practice of cosmetic surgery and regenerative medical aesthetics. Avagenesis' development activities are focused on the complex task of efficiently isolating high quality, viable and potent adipose-derived adult stem cells and regenerative cells using patent-pending and patented bioprocessing and cell isolation technology. For licensing and strategic reasons, all patent registrations, FDA registrations and other regulatory certificates are arranged through an exclusive licensing agreement with a related and affiliated company.

Neither the Exchange nor its regulation services provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Avagenesis' current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that Avagenesis may not successfully transition to a clinical stage company and the risk that Avagenesis may not successfully execute its development and commercialization activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to Avagenesis. Avagenesis cautions the reader that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and Avagenesis is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained *herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.*

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. securities laws.

Further Information

For further information, please contact:

Avagenesis Corp.
Alan Tam, PFP, CPA, CA
Chief Financial Officer
Telephone: (604) 377-7575